HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Jun Ohashi Selected Research

Resistin

1/2010A at single nucleotide polymorphism-358 is required for G at -420 to confer the highest plasma resistin in the general Japanese population.
9/2009PPARgamma Pro12Ala Pro/Pro and resistin SNP-420 G/G genotypes are synergistically associated with plasma resistin in the Japanese general population.
1/2009A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes.
7/2008Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes.
2/2008Serum resistin is reduced by glucose and meal loading in healthy human subjects.
11/2007Frequency of the G/G genotype of resistin single nucleotide polymorphism at -420 appears to be increased in younger-onset type 2 diabetes.
6/2007Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population.
4/2007Serum resistin is associated with the severity of microangiopathies in type 2 diabetes.
9/2005Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes.
10/2004The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Jun Ohashi Research Topics

Disease

17Malaria
08/2014 - 01/2002
13Insulin Resistance
09/2010 - 03/2002
10Cerebral Malaria
01/2012 - 01/2002
6Falciparum Malaria (Plasmodium falciparum Malaria)
12/2011 - 08/2002
6Schizophrenia (Dementia Praecox)
05/2010 - 08/2002
5Hypertension (High Blood Pressure)
03/2013 - 09/2003
5Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2010 - 12/2002
4Infection
01/2014 - 01/2002
4Obesity
01/2013 - 09/2003
3Type 2 Diabetes Mellitus (MODY)
09/2014 - 10/2004
2Type 1 Diabetes Mellitus (Autoimmune Diabetes)
09/2014 - 04/2008
2Rheumatoid Arthritis
01/2012 - 01/2010
2Diabetic Angiopathies (Diabetic Angiopathy)
03/2008 - 04/2007
1Hypersensitivity (Allergy)
09/2014
1Liver Diseases (Liver Disease)
06/2014
1Hepatocellular Carcinoma (Hepatoma)
01/2014
1Disease Progression
01/2014
1Chronic Hepatitis B
01/2014
1Tuberculosis (Tuberculoses)
05/2012
1Interstitial Lung Diseases (Interstitial Lung Disease)
01/2012
1Disease Susceptibility (Diathesis)
02/2011
1Body Weight (Weight, Body)
03/2010
1Narcolepsy
11/2008
1Cataplexy
11/2008
1Atherosclerosis
07/2008
1Autistic Disorder (Autism)
06/2008
1Diabetic Retinopathy (Retinopathy, Diabetic)
03/2008
1Nephritis
01/2008
1Breast Neoplasms (Breast Cancer)
11/2007
1Hypotension (Low Blood Pressure)
06/2007

Drug/Important Bio-Agent (IBA)

12ResistinIBA
01/2010 - 03/2002
10AntigensIBA
01/2014 - 08/2002
3Insulin (Novolin)FDA Link
09/2014 - 03/2002
3DNA (Deoxyribonucleic Acid)IBA
08/2014 - 11/2007
3InterferonsIBA
05/2012 - 03/2008
3Hemoglobin EIBA
12/2008 - 01/2003
2Glucose (Dextrose)FDA LinkGeneric
01/2009 - 07/2008
2beta-Globins (beta Globin)IBA
12/2008 - 01/2003
2HLA-DRB1 antigen (HLA DRB1)IBA
11/2008 - 02/2005
2Fc gamma receptor IIAIBA
12/2002 - 10/2002
1AutoantibodiesIBA
09/2014
1rocuronium (rocuronium bromide)FDA LinkGeneric
06/2014
1SugammadexIBA
06/2014
1remifentanil (Ultiva)FDA Link
06/2014
1Propofol (Diprivan)FDA LinkGeneric
06/2014
1HLA-DPB1 (HLA DPB1)IBA
01/2014
1HLA-DPA1 (HLA DPA1)IBA
01/2014
1Protein CIBA
01/2014
1HLA-DQ Antigens (HLA-DQ)IBA
01/2014
1HLA-DP Antigens (HLA-DP)IBA
01/2014
1AngiotensinogenIBA
03/2013
1GTP-Binding Proteins (G-Protein)IBA
03/2013
1Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
03/2013
1Adrenergic Receptors (Adrenergic Receptor)IBA
01/2013
1KIR ReceptorsIBA
01/2012
1Immunoglobulins (Immunoglobulin)IBA
01/2012
1Carbon MonoxideIBA
01/2012
1LigandsIBA
01/2012
1Pyrimethamine (Daraprim)FDA Link
12/2011
1Chloroquine (Aralen)FDA LinkGeneric
12/2011
1Diffuse panbronchiolitisIBA
02/2011
1MucinsIBA
02/2011
1von Willebrand FactorIBA
01/2011
1ThrombospondinsIBA
01/2011
1Endocannabinoids (Endocannabinoid)IBA
05/2010
1CB2 Cannabinoid ReceptorIBA
05/2010
1Leptin ReceptorsIBA
03/2010
1LeptinIBA
03/2010
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2010
1interferon gamma receptorIBA
12/2009
1Interferon-gamma (Interferon, gamma)IBA
12/2009
1Interferon Type IIBA
06/2009
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
02/2009
1Interleukin-5 (Interleukin 5)IBA
01/2009
1Interleukin-13IBA
01/2009
1adjuvant P40 (P 40)IBA
01/2009
1Merozoite Surface Protein 1 (MSA1)IBA
01/2009
1Interleukin-12 (IL 12)IBA
01/2009
1pioglitazone (Actos)FDA Link
01/2009
1Interleukin-4 (Interleukin 4)IBA
01/2009
1Complement Receptors (Complement Receptor)IBA
12/2008
1orexins (orexin)IBA
11/2008
1human HLA-DQB1 proteinIBA
11/2008
1Mitogen-Activated Protein Kinase 8IBA
07/2008
1Serine (L-Serine)FDA Link
07/2008
1Triglycerides (Triacylglycerol)IBA
07/2008
1Phosphotransferases (Kinase)IBA
07/2008
1Insulin Receptor Substrate ProteinsIBA
07/2008
1Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA
06/2008
1Iodide Peroxidase (Deiodinase)IBA
04/2008
1C-PeptideIBA
04/2008
1ICA512 autoantibodyIBA
04/2008
1AdiponectinIBA
03/2008
1CreatinineIBA
03/2008
1AdipokinesIBA
02/2008
1Neuregulin-1 (Neuregulin 1)IBA
01/2008
1AntibodiesIBA
01/2008
1C-Reactive ProteinIBA
06/2007

Therapy/Procedure

1Anesthesia
06/2014
1Radiotherapy
11/2007